This report came up on the BBC news website recently, and is now also reported on NHS choices.
nhs.uk/news/2011/02February/Pages/enzyme-blocks-cancer-spread.aspx
This is the BBC report:
bbc.co.uk/news/health-12525109
Cheryl
Hi Cheryl
This LOXL2 research is really encouraging. We had a brief discussion about it here a few weeks ago - can’t remember which thread. I have since discovered that there has been a patent request for a LOXL2 inhibitor drug, so let’s hope they get a move on with it.
finty x
I find it difficult to keep up sometimes. At least I can blame it on chemo for now.
Cheryl
You probably missed it - just a couple comments on a thread. x
Really interesting development - thanks for sharing info with us
Fran
Hi Cheryl,
Ive not seen this before so must have missed it also, thanks for shareing the info, it looks very promising doesnt it.
Linda x
Even if some of this is too late for our treatment, let’s hope there is better for women further down the line.
Cheryl
Yes it does look promising especially for ER- Breast cancer.
was interesting to that the NHS article pointed out that it was research done on ER- BC and that “The preliminary research was conducted in cell cultures and mice. This limits its direct relevance to humans at this stage”.But it does look really promising
But the BBC news never mentioned these two facts.
Melxx
News reports generally seem to leave out some very important steps that still need to be carried out, don’t they? But the more the genetic factors in BC are understood including the genetics of the actual cancers and the factors involved in spread, the better the eventual cures and perhaps preventions may be.
Cheryl
Just think why can they not report that there are different types of BC and that it is not a one size fits all disease.This could be a big break through for ER- cancer.
“Conclusion
The researchers presented experimental evidence that the LOXL2 protein may be involved in cancer spread in mouse models of breast cancer. It should be noted that this research was in oestrogen receptor negative tumours, so the results may not apply to other types of breast cancer. Further research is needed to see if LOXL2 plays a role in other breast cancer sub-types.”